Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.
Munuganti RS, Leblanc E, Axerio-Cilies P, Labriere C, Frewin K, Singh K, Hassona MD, Lack NA, Li H, Ban F, Tomlinson Guns E, Young R, Rennie PS, Cherkasov A. Munuganti RS, et al. Among authors: lack na. J Med Chem. 2013 Feb 14;56(3):1136-48. doi: 10.1021/jm3015712. Epub 2013 Jan 18. J Med Chem. 2013. PMID: 23301637
Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer.
Li H, Hassona MD, Lack NA, Axerio-Cilies P, Leblanc E, Tavassoli P, Kanaan N, Frewin K, Singh K, Adomat H, Böhm KJ, Prinz H, Guns ET, Rennie PS, Cherkasov A. Li H, et al. Among authors: lack na. Mol Cancer Ther. 2013 Nov;12(11):2425-35. doi: 10.1158/1535-7163.MCT-13-0267. Epub 2013 Aug 12. Mol Cancer Ther. 2013. PMID: 23939374
Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer.
Ban F, Leblanc E, Cavga AD, Huang CF, Flory MR, Zhang F, Chang MEK, Morin H, Lallous N, Singh K, Gleave ME, Mohammed H, Rennie PS, Lack NA, Cherkasov A. Ban F, et al. Among authors: lack na. Cancers (Basel). 2021 Jul 12;13(14):3488. doi: 10.3390/cancers13143488. Cancers (Basel). 2021. PMID: 34298700 Free PMC article.
Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.
Leblanc E, Ban F, Cavga AD, Lawn S, Huang CF, Mohan S, Chang MEK, Flory MR, Ghaidi F, Lingadahalli S, Chen G, Yu IPL, Morin H, Lallous N, Gleave ME, Mohammed H, Young RN, Rennie PS, Lack NA, Cherkasov A. Leblanc E, et al. Among authors: lack na. J Med Chem. 2021 Oct 28;64(20):14968-14982. doi: 10.1021/acs.jmedchem.1c00681. Epub 2021 Oct 18. J Med Chem. 2021. PMID: 34661404
EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities.
Yedier-Bayram O, Gokbayrak B, Kayabolen A, Aksu AC, Cavga AD, Cingöz A, Kala EY, Karabiyik G, Günsay R, Esin B, Morova T, Uyulur F, Syed H, Philpott M, Cribbs AP, Kung SHY, Lack NA, Onder TT, Bagci-Onder T. Yedier-Bayram O, et al. Among authors: lack na. Cell Death Dis. 2022 Aug 16;13(8):710. doi: 10.1038/s41419-022-05146-4. Cell Death Dis. 2022. PMID: 35973998 Free PMC article.
62 results